DENCODA’s mission is to address critical research and diagnostic detection challenges.

We’re leaders in the DNA and protein technological revolution.

2024

•Dencoda has been awarded a Phase I Small Business Innovation Research (SBIR) grant of$274,000 from the National Science Foundation (NSF).

‍

2023

Awarded from the Indiana Small Business Development Center for the Indiana Technical Assistance Program (INTAP) ($12,500)

2022

Awarded Phase I SBIR from NIAMS ($256,000): Matrix-Metallo-Protease
SBIR matching fund from Elevate Venture ($50,000)
Purdue Boost Accelerator program ($5,000)

2021

National NSF I-Corps (105 interviews) ($50,000)-Kinase assay
NIAID Application Assistance Program/ DOE Phase I Assistance Program

2020

Won Elevate Venture Pitch Competition ($20,000)
Awarded NSF-EAGER- co-PI ($300,000) with Purdue University: Kinase assay
Participated in Nexus Origin

2019

DENCODA was founded
NCI Application Assistance Program
Participated NSF I-Corps Midwest

2018

Participated Purdue Foundry Firestarter

Our team

We have an experienced team that are leaders in the molecular and biochemical diagnostics field.

Dongwook Kim

Founder & CEO

Alex Valencia Ph.D.

Chief Technology Officer

Adam Friedman Ph.D.

Business Development Consultant

Our advisors & consultants

Our advisors and consultants have been involved in establishing DENCODA’s groundbreaking technology.

Casey Krusemark, Ph.D.

Scientific Advisor & Co-inventor

Associate Professor, Purdue University

Chelsea Bahner Ph.D.

Research Partner

Principal Investigator, Steadman Philippon Research Institute

Chris Emery M.D.

Clinical Research Partner

Professor, Clinical Pathology Lab Director, Indiana University Hospital

Steve Charlebois, Ph.D.